Global Antacids Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Proton Pump Inhibitors, H2 Antagonists, and Acid Neutralizers

By Dosage Form;

Tablet, Liquid, and Powder

By Route of Administration;

Oral and Injectable

By Indication;

Gastroesophageal Reflux Disease, Heartburn, Peptic Ulcer, and Others

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn123778639 Published Date: May, 2025 Updated Date: June, 2025

Antacids Market Overview

Antacids Market (USD Million)

Antacids Market was valued at USD 6,767.33 million in the year 2024. The size of this market is expected to increase to USD 8,436.75 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 3.2%.


Global Antacids Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 3.2 %


Study Period2025 - 2031
Base Year2024
CAGR (%)3.2 %
Market Size (2024)USD 6,767.33 Million
Market Size (2031)USD 8,436.75 Million
Market ConcentrationHigh
Report Pages315
6,767.33
2024
8,436.75
2031

Major Players

  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Dr. Reddys Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Pfizer Inc.
  • The Procter & Gamble Company
  • Reckitt Benckiser Group Plc
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Antacids Market

Fragmented - Highly competitive market without dominant players


The Antacids Market is witnessing robust expansion as gastrointestinal issues like indigestion and acid reflux become more prevalent. An estimated 30% of the population experiences gastric discomfort, boosting demand for fast-acting relief options. The accessibility and rapid effectiveness of antacids make them a widely favored solution.

Technological and Product Innovations
Innovative formats such as chewable tablets, flavored liquids, and effervescent powders are redefining the consumer experience. Approximately 20% of newly introduced products in the market offer dual-action or multi-symptom relief, enhancing treatment effectiveness and convenience.

Regulatory and Healthcare Dynamics
The shift toward self-medication and over-the-counter solutions is reshaping the industry. With over 40% of users opting for self-managed care, transparency in formulation and accessible packaging is becoming increasingly important.

Future Outlook
Looking ahead, growth is expected to be sustained by rising consumer preference for natural and convenient remedies. With more than 35% of users leaning towards herbal or sugar-free variants, the market is evolving toward more inclusive and health-conscious offerings, ensuring long-term relevance and expansion.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Dosage Form
    3. Market Snapshot, By Route of Administration
    4. Market Snapshot, By Indication
    5. Market Snapshot, By Distribution Channel
    6. Market Snapshot, By Region
  4. Antacids Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Prevalence of Gastroesophageal Reflux Disease (GERD)
        2. Growing Awareness of Digestive Health
        3. Rising Stress and Lifestyle Factors Contributing to Acid-related Disorders
        4. Expansion of Over-the-Counter (OTC) Medication Availability
      2. Restraints
        1. Potential Side Effects and Health Risks
        2. Competition from Alternative Treatments
        3. Regulatory Challenges and Compliance Issues
        4. Consumer Misuse and Over-reliance on Antacids
      3. Opportunities
        1. Rising Demand for Natural and Organic Antacid Products
        2. Development of Targeted Formulations for Specific Demographics
        3. Innovations in Delivery Methods and Product Formats
        4. Increasing Focus on Preventive Healthcare
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Antacids Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Proton Pump Inhibitors
      2. H2 Antagonists
      3. Acid Neutralizer
    2. Antacids Market, By Dosage Form, 2021 - 2031 (USD Million)
      1. Tablet
      2. Liquid
      3. Powder
    3. Antacids Market, By Route of Administration, 2021 - 2031 (USD Million)
      1. Oral
      2. Injectable
    4. Antacids Market, By Indication, 2021 - 2031 (USD Million)
      1. Gastroesophageal Reflux Disease
      2. Heartburn
      3. Peptic Ulcer
      4. Others
    5. Antacids Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    6. Antacids Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. AstraZeneca Plc
      2. Bayer AG
      3. Boehringer Ingelheim GmbH
      4. Dr. Reddys Laboratories Ltd.
      5. GlaxoSmithKline Plc
      6. Johnson & Johnson
      7. Pfizer Inc.
      8. The Procter & Gamble Company
      9. Reckitt Benckiser Group Plc
      10. Sanofi S.A.
      11. Sun Pharmaceutical Industries Limited
  7. Analyst Views
  8. Future Outlook of the Market